Diving into the complexities of sustainability in healthcare packaging that include circular economy strategies, takeback ...

Sogroya (somapacitan injection) has been recommended by UK health technology assessor the National Institute for Health and ...

Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

Novo Nordisk has strengths, including a deep pipeline, that should help it overcome recent obstacles. Cava Group's results ...

Eli Lilly, the global pharmaceutical giant, said the Therapeutic Goods Administration had approved the use of its Mounjaro ...

Inception cohort study consolidates the role of intestinal ultrasound for disease prognosis and treatment monitoring over 12 ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

The US drugmaker has stolen a march on Novo Nordisk by bringing a viable oral weight-loss medicine, orforglipron, into successful phase 3 clinical trials. An oral version is the holy grail for drugs ...

Japanese drugmaker Sumitomo Pharma (TYO: 4506) and Denmark’s Novo Nordisk (NOV: N) have entered into a co-promotion agreement ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...